The intratumor levels of RSL1D1 protein were effectively downregulated by siRSL1D1 treatment in both p53+/+ and p53−/− xenografts (Fig. 8A), leading to a significant inhibition of tumor growth (Fig. 8B and C). The gene discussed is TP53; the disease is neoplasm.